GRI Bio, Inc. GRI
2.05
(0.04)
(1.91%)
as of 25 Sep
- Market cap
- $4.6M
- P/E
- 0.0×
Follow GRI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (142.02%) | (185.67%) | (238.17%) | (465.42%) |
+8 more TTM periods Free account |
|
| (113.27%) | (141.84%) | (166.00%) | (256.91%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(94.36%) | (104.01%) | (200.87%) | (678.44%) | |
Free Cash Flow per Share |
(5.77) | (9.78) | (103.84) | (98.44) | |
Free Cash Flow |
(10.41) | (12.13) | (10.20) | (9.21) | |
Capital Expenditures |
— | — | (0.01) | — | |
| Other line items | |||||
Cash ROIC |
(49.06%) | (56.20%) | (71.55%) | (152.35%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.08 | 1.11 | 0.85 | 0.70 | |
Depreciation/Fixed assets |
1.50 | 2.00 | 1.33 | 4.00 | |
Capex/Depreciation |
0.00 | 0.00 | (2.75) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.77) | (9.78) | (103.73) | (98.44) | |
Capex per Share |
0.00 | 0.00 | (0.11) | 0.00 | |
Capex to Sales |
— | — | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates